Hepatitis B — NZ Condition Guide | KiwiMeds

What is Hepatitis B?

Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). It can be acute (short-term) or chronic (long-term). Chronic hepatitis B infection increases the risk of liver cirrhosis and liver cancer. In New Zealand, hepatitis B disproportionately affects Māori, Pacific peoples, and Asian communities.

Overview

Most adults who get hepatitis B clear the infection within 6 months (acute hepatitis B). However, 90% of babies infected at birth and 5% of adults infected develop chronic hepatitis B. Chronic hepatitis B is usually “silent” — causing no symptoms for years or decades. When symptoms do occur, they can include fatigue, abdominal discomfort, jaundice (yellowing of skin and eyes), and dark urine. Complications include cirrhosis and hepatocellular carcinoma (liver cancer).

Treatment in New Zealand

There is no cure for chronic hepatitis B, but antiviral medications can suppress viral replication and reduce the risk of cirrhosis and liver cancer. Tenofovir and entecavir are the preferred antivirals — both are funded by Pharmac for eligible patients with chronic hepatitis B. Regular monitoring (HBV DNA, liver enzymes, liver ultrasound) is important. Hepatitis B vaccination is the most effective prevention strategy.

NZ-Specific Information

New Zealand has a free hepatitis B immunisation programme — the hepatitis B vaccine is included in the childhood immunisation schedule and is free for those in high-risk groups. Screening for hepatitis B is recommended for Māori, Pacific, and Asian peoples. Hepatitis NZ (hepatitisnz.org.nz) provides support. Many Māori and Pacific peoples carry chronic hepatitis B unknowingly — community screening programmes are vital.

Frequently Asked Questions

Can hepatitis B be transmitted through casual contact? No — hepatitis B is transmitted through blood-to-blood contact, sexual contact, and from mother to baby at birth. It is not spread by hugging, sharing food, or casual contact. If I have hepatitis B, can I drink alcohol? Alcohol significantly increases the risk of liver damage in people with hepatitis B — it should be minimised or avoided.

Supplements That May Support Management

⚠️ Important: The supplements listed below have varying levels of clinical evidence. They are not a substitute for prescribed medications and should only be considered as adjunctive support under the guidance of a qualified healthcare professional. Always inform your GP or pharmacist before commencing any supplement, as interactions with prescribed medicines are possible.

• Vitamin D — Vitamin D has immunomodulatory effects that may support immune control of hepatitis B viral replication. Deficiency is associated with higher viral loads and worse liver outcomes. Supplementation is recommended where deficiency is confirmed.
• Vitamin E (as adjunct to antiviral therapy) — Vitamin E has antioxidant properties that may reduce hepatic oxidative stress and liver enzyme elevation in chronic hepatitis B. However, long-term high-dose vitamin E supplementation carries cardiovascular risks and should not exceed safe limits without medical supervision.
• Milk Thistle (Silymarin) — Silymarin from milk thistle has hepatoprotective antioxidant properties and has demonstrated modest liver enzyme normalisation benefits in viral hepatitis in some trials. It may be used as a complementary support but does not replace antiviral therapy.
• Selenium — Selenium has antiviral properties and hepatoprotective effects. Deficiency is more common in chronic hepatitis B and is associated with worse liver outcomes. Supplementation at RDI levels (55–100 mcg/day) may provide supportive benefit.

Relevant Vaccinations

Individuals living with hepatitis B may benefit from the following vaccinations. Please discuss your vaccination status with your GP or practice nurse, as eligibility and funding through the New Zealand National Immunisation Schedule may apply.

• Hepatitis B (primary vaccination) — Three-dose hepatitis B vaccination (at 0, 1, 6 months) provides >95% protection against hepatitis B infection. This is the fundamental preventive measure for HBV exposure. In NZ it is included in the childhood immunisation schedule. Adults who are not immune should be vaccinated.
• Hepatitis A — Co-infection with hepatitis A worsens hepatitis B outcomes. Hepatitis A vaccination is strongly recommended for people with chronic hepatitis B.
• Influenza (annual) — Influenza can accelerate liver inflammation in chronic hepatitis B. Annual vaccination is recommended.
• Pneumococcal — Liver disease impairs immune function. Pneumococcal vaccination is recommended for those with significant liver disease.

Dietary Guidance

Evidence-based dietary modifications play a meaningful role in the management of hepatitis B. The following foods are generally recommended as part of a balanced, condition-appropriate diet. A referral to a registered dietitian may be beneficial for personalised nutritional planning.

• Liver-protective diet (Mediterranean pattern) — A Mediterranean dietary pattern reduces hepatic steatosis, inflammation, and fibrosis progression, which are common complications of chronic hepatitis B.
• Cruciferous vegetables — Indole-3-carbinol and sulforaphane support hepatic detoxification enzyme activity and provide antioxidant support for the liver.
• Coffee (regular consumption) — Strong epidemiological evidence supports that regular coffee consumption (2–4 cups/day) reduces progression of liver fibrosis and cirrhosis in chronic liver disease. Caffeinated coffee appears most beneficial.
• Limit: alcohol — Alcohol and hepatitis B have a synergistic liver-damaging effect, significantly increasing the risk of cirrhosis and hepatocellular carcinoma. Abstinence from alcohol is strongly recommended in chronic hepatitis B.
• Limit: iron-rich red meat and iron supplements — Hepatic iron overload worsens liver injury in viral hepatitis. Unless iron deficiency is confirmed, avoid excess iron supplementation.

Related Conditions & Medications

Related conditions: Liver Disease. Related medications: Tenofovir.